Long-Term Outcome of Endoscopic Resection vs. Surgery for Early Gastric Cancer: A Non-inferiority-Matched Cohort Study

Abstract

Endoscopic resection might not be inferior to surgery with respect to OS in patients with EGC lesions that meet the absolute or expanded criteria. However, DFS, RFS, and metachronous RFS might be lower after endoscopic resection than after surgery.

Exploring the Evidence of Expanded Criteria for Endoscopic Resection of Early Gastric Cancers

“…Moreover, the complication rates were much lower after ESD (5.1%) than after gastrectomy (15.0%). The reported results were similar to those of recent studies that showed a comparable long-term outcome of ESD in terms of overall survival rate with that of surgery, including lower complication rates [5,7,8]. The length of hospital stay and the treatment costs in ESD treatment were superior to those in surgery for early gastric cancer within the expanded indication, as previously reported [9].…”

Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma

“…Previous reports on adverse events after endoscopic resection and surgery have been inconsistent. Although some reported that adverse events occurred less frequently in the ESD group than the surgery group, others found no difference between the two groups [10,22,23]. In our study, treatment-related adverse event rates were similar between the two groups.…”

“…ESD has been considered a feasible alternative to surgical resection for tumors with mucosal or minute submucosal invasion, because for these tumors there is little or no risk of lymph node metastasis [17,20]. Several recent studies have compared the clinical and oncological outcomes of ESD with gastrectomy, demonstrating favorable outcomes of ESD in terms of survival as well as perioperative outcomes [10,[21][22][23]. The long-term outcomes of ESD were comparable to that of gastrectomy, even when the analysis was restricted to EGC that met the expanded criteria [10].…”

Dysregulated lncRNA-UCA1 contributes to the progression of gastric cancer through regulation of the PI3K-Akt-mTOR signaling pathway

“…Despite improvements in gastrointestinal endoscopy and surgery, the prognoses of advanced gastric cancer patients remain poor, with a 5-year survival percentage of < 30% [20][21][22]. Studies of the molecular mechanisms involved in different stages of gastric cancer are urgently needed for the development of better methods of diagnoses and improvements in therapeutic treatments for this disorder.…”